To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
The 2022 Hour Detroit’s Top Docs List is out and 35 physicians from Barbara Ann Karmanos Cancer Institute are named top doctors under 20 different specialties. Each year, Hour Detroit Magazine puts out an online peer-to-peer review survey conducted by Professional Research Services (PRS) to determine the top physicians in southeastern Michigan (Wayne, Oakland, Macomb, Washtenaw and Livingston Counties). Participating physicians in the aforementioned counties are asked to nominate a doctor who they view ...
Karmanos Cancer Institute continues to advance the treatment for cancer patients with a new Varian Ethos™ therapy system, available at its premier specialty cancer hospital, Karmanos Cancer Center , in Detroit, Michigan. This new system is an artificial intelligence (AI)-driven holistic solution designed to increase the capability, flexibility and efficiency of radiotherapy. This machine is able to deliver an adaptive therapy, a treatment plan that accounts for daily changes in tumor and normal anatomy,...
The New England Journal of Medicine Congratulations to Nitin Vaishampayan, M.D., radiation oncologist at Karmanos Cancer Institute. Dr. Vaishampayan co-authored a paper that was recently published by The New England Journal of Medicine titled "Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer." Click here to view the article.